Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
S0916, MLN1202 in Treating Patients With Bone Metastases
NCT01015560 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works in treating patients with bone metastases.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- GENETIC polymorphism analysis
- DRUG anti-CCR2 monoclonal antibody MLN1202
Study Locations (20)
Kansas
- Cancer Center of Kansas, PA - Chanute — Chanute
- Cancer Center of Kansas, PA - Dodge City — Dodge City
- Cancer Center of Kansas, PA - El Dorado — El Dorado
- Cancer Center of Kansas - Fort Scott — Fort Scott
- Cancer Center of Kansas-Independence — Independence
- Cancer Center of Kansas, PA - Kingman — Kingman
- Lawrence Memorial Hospital — Lawrence
- Cancer Center of Kansas, PA - Liberal — Liberal
- Cancer Center of Kansas, PA - Newton — Newton
- Cancer Center of Kansas, PA - Parsons — Parsons
- Cancer Center of Kansas, PA - Pratt — Pratt
- Cancer Center of Kansas, PA - Salina — Salina
- Cancer Center of Kansas, PA - Wellington — Wellington
- Associates in Womens Health, PA - North Review — Wichita
- Cancer Center of Kansas, PA - Medical Arts Tower — Wichita
California
- Glendale Memorial Hospital Comprehensive Cancer Center — Glendale
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles
Indiana
- St. Francis Hospital and Health Centers - Beech Grove Campus — Beech Grove
- Reid Hospital & Health Care Services — Richmond
Illinois
- Cardinal Bernardin Cancer Center at Loyola University Medical Center — Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01015560
The ClinicalTrials.gov registry entry for NCT01015560 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 3 interventions — of which laboratory biomarker analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01015560 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Kansas, California, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01015560 about?
NCT01015560 is a clinical study titled "S0916, MLN1202 in Treating Patients With Bone Metastases". RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works i...
What is the current status of trial NCT01015560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2010-03. Estimated completion is 2012-12.
What conditions does trial NCT01015560 study?
This clinical trial studies the following conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01015560?
The interventions under investigation include: laboratory biomarker analysis (OTHER), polymorphism analysis (GENETIC), anti-CCR2 monoclonal antibody MLN1202 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01015560?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01015560 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.